Androgen replacement and/or 5 alpha reductase inhibitors in aging men.
A case study of a typical 65 year old man with symptoms of both LUTS with established BPH, and andropause, is presented. The case for 5ARI therapy versus androgen replacement therapy is discussed, and the evidence for the use of these drugs in combination is reviewed.
Klotz
Laurence H
LH
Division of Urology, University of Toronto, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada.
D000367:Age Factors; D000368:Aged; D000728:Androgens / Q000627:therapeutic use*; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors*; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
D000728:Androgens; D042944:Cholestenone 5 alpha-Reductase